Cargando…

Local and Systemic RAGE Axis Changes in Pulmonary Hypertension: CTEPH and iPAH

OBJECTIVE: The molecular determinants of chronic thromboembolic pulmonary hypertension (CTEPH) and idiopathic pulmonary arterial hypertension (iPAH) remain poorly understood. The receptor for advanced glycation endproducts (RAGE) and its ligands: HMGB1 and S100A9 are involved in inflammatory disorde...

Descripción completa

Detalles Bibliográficos
Autores principales: Moser, Bernhard, Megerle, Anna, Bekos, Christine, Janik, Stefan, Szerafin, Tamás, Birner, Peter, Schiefer, Ana-Iris, Mildner, Michael, Lang, Irene, Skoro-Sajer, Nika, Sadushi-Kolici, Roela, Taghavi, Shahrokh, Klepetko, Walter, Ankersmit, Hendrik Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4154707/
https://www.ncbi.nlm.nih.gov/pubmed/25188497
http://dx.doi.org/10.1371/journal.pone.0106440
_version_ 1782333459302187008
author Moser, Bernhard
Megerle, Anna
Bekos, Christine
Janik, Stefan
Szerafin, Tamás
Birner, Peter
Schiefer, Ana-Iris
Mildner, Michael
Lang, Irene
Skoro-Sajer, Nika
Sadushi-Kolici, Roela
Taghavi, Shahrokh
Klepetko, Walter
Ankersmit, Hendrik Jan
author_facet Moser, Bernhard
Megerle, Anna
Bekos, Christine
Janik, Stefan
Szerafin, Tamás
Birner, Peter
Schiefer, Ana-Iris
Mildner, Michael
Lang, Irene
Skoro-Sajer, Nika
Sadushi-Kolici, Roela
Taghavi, Shahrokh
Klepetko, Walter
Ankersmit, Hendrik Jan
author_sort Moser, Bernhard
collection PubMed
description OBJECTIVE: The molecular determinants of chronic thromboembolic pulmonary hypertension (CTEPH) and idiopathic pulmonary arterial hypertension (iPAH) remain poorly understood. The receptor for advanced glycation endproducts (RAGE) and its ligands: HMGB1 and S100A9 are involved in inflammatory disorders. We sought to investigate the role of the RAGE axis in patients with CTEPH undergoing pulmonary endarterectomy (PEA), iPAH undergoing lung transplantation (LuTX). The high pulmonary vascular resistance in CTEPH/iPAH results in pressure overload of the right ventricle. We compared sRAGE measurements to that of patients with aortic valve stenosis (AVS) – pressure overload of the left ventricle. METHODS: We enrolled patients with CTEPH(26), iPAH(15), AVS(15) and volunteers(33). Immunohistochemistry with antibodies to RAGE and HMGB1 was performed on PEA specimens and lung tissues. We employed enzyme-linked immunosorbent assays to determine the concentrations of sRAGE, esRAGE, HMGB1 and S100A9 in serum of volunteers and patients with CTEPH, iPAH, AVS before and after PEA, LuTX and aortic valve replacement (AVR). RESULTS: In endarterectomised tissues from patients with CTEPH RAGE and HMGB1 were identified in myofibroblasts (α-SMA(+)vimentin(+)CD34(−)), recanalizing vessel-like structures of distal myofibrotic tissues and endothelium of neointima. RAGE was differentially expressed in prototypical Heath Edwards lesions in iPAH. We found significantly increased serum concentrations of sRAGE, esRAGE and HMGB1 in CTEPH. In iPAH, sRAGE and esRAGE were significantly higher than in controls. Serum concentrations of sRAGE were significantly elevated in iPAH(p<0.001) and CTEPH(p = 0.001) compared to AVS. Serum sRAGE was significantly higher in iPAH compared to CTEPH(p = 0.042) and significantly reduced in AVS compared to controls(p = 0.001). There were no significant differences in sRAGE serum concentrations before and after surgical therapy for CTEPH, iPAH or AVS. CONCLUSIONS: Our data suggest a role for the RAGE pathway in the pathophysiology of CTEPH and iPAH. PEA improves the local control of disease but may not influence the systemic inflammatory mechanisms in CTEPH patients through the RAGE pathway.
format Online
Article
Text
id pubmed-4154707
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-41547072014-09-08 Local and Systemic RAGE Axis Changes in Pulmonary Hypertension: CTEPH and iPAH Moser, Bernhard Megerle, Anna Bekos, Christine Janik, Stefan Szerafin, Tamás Birner, Peter Schiefer, Ana-Iris Mildner, Michael Lang, Irene Skoro-Sajer, Nika Sadushi-Kolici, Roela Taghavi, Shahrokh Klepetko, Walter Ankersmit, Hendrik Jan PLoS One Research Article OBJECTIVE: The molecular determinants of chronic thromboembolic pulmonary hypertension (CTEPH) and idiopathic pulmonary arterial hypertension (iPAH) remain poorly understood. The receptor for advanced glycation endproducts (RAGE) and its ligands: HMGB1 and S100A9 are involved in inflammatory disorders. We sought to investigate the role of the RAGE axis in patients with CTEPH undergoing pulmonary endarterectomy (PEA), iPAH undergoing lung transplantation (LuTX). The high pulmonary vascular resistance in CTEPH/iPAH results in pressure overload of the right ventricle. We compared sRAGE measurements to that of patients with aortic valve stenosis (AVS) – pressure overload of the left ventricle. METHODS: We enrolled patients with CTEPH(26), iPAH(15), AVS(15) and volunteers(33). Immunohistochemistry with antibodies to RAGE and HMGB1 was performed on PEA specimens and lung tissues. We employed enzyme-linked immunosorbent assays to determine the concentrations of sRAGE, esRAGE, HMGB1 and S100A9 in serum of volunteers and patients with CTEPH, iPAH, AVS before and after PEA, LuTX and aortic valve replacement (AVR). RESULTS: In endarterectomised tissues from patients with CTEPH RAGE and HMGB1 were identified in myofibroblasts (α-SMA(+)vimentin(+)CD34(−)), recanalizing vessel-like structures of distal myofibrotic tissues and endothelium of neointima. RAGE was differentially expressed in prototypical Heath Edwards lesions in iPAH. We found significantly increased serum concentrations of sRAGE, esRAGE and HMGB1 in CTEPH. In iPAH, sRAGE and esRAGE were significantly higher than in controls. Serum concentrations of sRAGE were significantly elevated in iPAH(p<0.001) and CTEPH(p = 0.001) compared to AVS. Serum sRAGE was significantly higher in iPAH compared to CTEPH(p = 0.042) and significantly reduced in AVS compared to controls(p = 0.001). There were no significant differences in sRAGE serum concentrations before and after surgical therapy for CTEPH, iPAH or AVS. CONCLUSIONS: Our data suggest a role for the RAGE pathway in the pathophysiology of CTEPH and iPAH. PEA improves the local control of disease but may not influence the systemic inflammatory mechanisms in CTEPH patients through the RAGE pathway. Public Library of Science 2014-09-04 /pmc/articles/PMC4154707/ /pubmed/25188497 http://dx.doi.org/10.1371/journal.pone.0106440 Text en © 2014 Moser et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Moser, Bernhard
Megerle, Anna
Bekos, Christine
Janik, Stefan
Szerafin, Tamás
Birner, Peter
Schiefer, Ana-Iris
Mildner, Michael
Lang, Irene
Skoro-Sajer, Nika
Sadushi-Kolici, Roela
Taghavi, Shahrokh
Klepetko, Walter
Ankersmit, Hendrik Jan
Local and Systemic RAGE Axis Changes in Pulmonary Hypertension: CTEPH and iPAH
title Local and Systemic RAGE Axis Changes in Pulmonary Hypertension: CTEPH and iPAH
title_full Local and Systemic RAGE Axis Changes in Pulmonary Hypertension: CTEPH and iPAH
title_fullStr Local and Systemic RAGE Axis Changes in Pulmonary Hypertension: CTEPH and iPAH
title_full_unstemmed Local and Systemic RAGE Axis Changes in Pulmonary Hypertension: CTEPH and iPAH
title_short Local and Systemic RAGE Axis Changes in Pulmonary Hypertension: CTEPH and iPAH
title_sort local and systemic rage axis changes in pulmonary hypertension: cteph and ipah
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4154707/
https://www.ncbi.nlm.nih.gov/pubmed/25188497
http://dx.doi.org/10.1371/journal.pone.0106440
work_keys_str_mv AT moserbernhard localandsystemicrageaxischangesinpulmonaryhypertensionctephandipah
AT megerleanna localandsystemicrageaxischangesinpulmonaryhypertensionctephandipah
AT bekoschristine localandsystemicrageaxischangesinpulmonaryhypertensionctephandipah
AT janikstefan localandsystemicrageaxischangesinpulmonaryhypertensionctephandipah
AT szerafintamas localandsystemicrageaxischangesinpulmonaryhypertensionctephandipah
AT birnerpeter localandsystemicrageaxischangesinpulmonaryhypertensionctephandipah
AT schieferanairis localandsystemicrageaxischangesinpulmonaryhypertensionctephandipah
AT mildnermichael localandsystemicrageaxischangesinpulmonaryhypertensionctephandipah
AT langirene localandsystemicrageaxischangesinpulmonaryhypertensionctephandipah
AT skorosajernika localandsystemicrageaxischangesinpulmonaryhypertensionctephandipah
AT sadushikoliciroela localandsystemicrageaxischangesinpulmonaryhypertensionctephandipah
AT taghavishahrokh localandsystemicrageaxischangesinpulmonaryhypertensionctephandipah
AT klepetkowalter localandsystemicrageaxischangesinpulmonaryhypertensionctephandipah
AT ankersmithendrikjan localandsystemicrageaxischangesinpulmonaryhypertensionctephandipah